Banz William J, Iqbal M J, Bollaert Michael, Chickris Nicole, James Bryce, Higginbotham D Allan, Peterson Richard, Murphy Laura
Department of Animal Science, Food and Nutrition, Southern Illinois University, Carbondale, IL 62901-4317, USA.
Phytomedicine. 2007 Oct;14(10):681-9. doi: 10.1016/j.phymed.2007.06.003. Epub 2007 Aug 8.
Asian ginseng (Panax ginseng) and its close relative North American ginseng (Panax quinquefolius) are perennial aromatic herbs that are widely used in Oriental medicine and have been acclaimed to have various health benefits including diabetes treatment. In this study, we compared the effects of a diet containing rosiglitazone to a diet containing ginseng (Panax quinquefolius) in male Zucker diabetic fatty (ZDF) rats. Animals were assigned to one of three diets: control, rosiglitazone (0.1 g/1 kg diet), or ginseng (10 g/1 kg diet). During the 11-week study, body weight, food intake, organ weight, blood glucose, plasma cholesterol, and plasma triglyceride levels were evaluated. Animals treated with rosiglitazone or ginseng exhibited increased body weight (p<0.05) and decreased kidney weight (p<0.05) compared to control animals. The rosiglitazone group demonstrated decreased food intake and plasma triglyceride levels versus the other groups (p<0.05). The ginseng group revealed decreased cholesterol levels relative to the control group (p<0.05). Furthermore, ginseng and rosiglitazone had marked effects on the expression of genes involved in PPAR actions and triglyceride metabolism compared to controls. In conclusion, ginseng modified the diabetic phenotype and genes associated with diabetes in the male ZDF rat. These data are encouraging, and warrant further research to determine the therapeutic value of this medicinal herb in treating human diabetes.
亚洲人参(人参)及其近缘种北美人参(西洋参)是多年生芳香草本植物,在东方医学中广泛应用,据称具有多种健康益处,包括治疗糖尿病。在本研究中,我们比较了含罗格列酮的饮食与含人参(西洋参)的饮食对雄性Zucker糖尿病脂肪大鼠(ZDF大鼠)的影响。将动物分为三种饮食组之一:对照组、罗格列酮组(0.1克/1千克饮食)或人参组(10克/1千克饮食)。在为期11周的研究中,评估了体重、食物摄入量、器官重量、血糖、血浆胆固醇和血浆甘油三酯水平。与对照动物相比,用罗格列酮或人参治疗的动物体重增加(p<0.05),肾脏重量减轻(p<0.05)。罗格列酮组与其他组相比,食物摄入量和血浆甘油三酯水平降低(p<0.05)。人参组相对于对照组胆固醇水平降低(p<0.05)。此外,与人参和罗格列酮对照组相比,它们对参与PPAR作用和甘油三酯代谢的基因表达有显著影响。总之,人参改变了雄性ZDF大鼠的糖尿病表型和与糖尿病相关的基因。这些数据令人鼓舞,值得进一步研究以确定这种草药在治疗人类糖尿病方面的治疗价值。